Industry perspectives on ICH guidelines

Statistics in Medicine

Volumn 21, Issue 19, 2002, Pages 2949-2957

  Rockhold, Frank W ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Drug development; Harmonization; International Conference on Harmonization (ICH); Regulatory

Indexed keywords

ARTICLE; CLINICAL RESEARCH; CONTROLLED STUDY; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; EUROPE; HEALTH CARE COST; HEALTH CARE NEED; JAPAN; METHODOLOGY; PRACTICE GUIDELINE; REGISTRATION; STANDARDIZATION; UNITED STATES;

DRUG APPROVAL; DRUG INDUSTRY; EUROPEAN UNION; GUIDELINES; HUMANS; INTERNATIONAL COOPERATION; JAPAN; LEGISLATION, DRUG; PHARMACEUTICAL PREPARATIONS; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0037108236     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1299     Document Type: Article

References (28)

1. FDA. FDA Guidelines for the Format and Content of the Clinical and Statistical Sections of a New Drug Application. FDA, Rockville, MD, U.S.A., 1988.
2. Kaitin KI, Healy EM. The new drug approvals of 1996, 1997, and 1998: drug development trends in the user fee era. Drug Information Journal 2000; 34:1-14.
3. Colby MA, Birt MP. Negotiating the gray maze: the business of medicine in Japan, 1997.
4. D'Arcy PF, Harron DWG (eds). Proceedings of the First International Conference on Harmonisation. Queen's University of Belfast, 1992.
5. Nutley C. The value and benefits of ICH to industry. International Conference on Harmonisation for Registration of Pharmaceuticals for Human Use, IFPMA, PhRMA, 2000.
6. Juillet Y. Thematic Session. International Conferences on Harmonization (ICH): Risks and Benefits. Special Session Dedicated to the Harmonization of Studies for the Purpose of the International Registration of Drugs. The Rationale and Organization of International Conferences on Harmonization, 1997.
7. Showalter J. International Conference on Harmonization. How the United States Food and Drug Administration will proceed. Journal of Biolaw & Business 1997; 1(2):90-93.
8. Barlon BL. International Conference on Harmonization - good clinical practices update. Drug Information Journal 1988; 32:1143-1147.
9. Increased clinical trial sizes could allow earlier detection of AEs, Woodcock says. Health News Daily 1999; 11/8.
10. Brown JS, Kaitin KI, McAuslane N, Thomas KE, Walker SR. Population exposure required to assess clinical safety: report to the International Conference on Harmonization Working Group. Drug Information Journal 1996; 30:17-27.
11. Goldsmith DI. The impact of the International Conference on Harmonization (ICH) on pharmacoepidemiology and pharmacovigilance. Pharmacoepidemiology and Drug Safety 1998; 7:289-291.
12. Electronic ADR implementation may require more than four years, firms say. The Pink Sheet 1999; 61/8.
13. Dixon JR. The International Conference on Harmonization good clinical practice guideline. Quality Assurance 1998; 6:65-74.
14. CPMP Working Party on Efficacy of Medicinal Products. Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products. Statistics in Medicine 1995; 14:1659-1682.
15. CPMP. Draft revision of Note for Guidance on Bioavailability/Bioequivalence. CPMP/EWP/QWP/1401/98, 1999.
16. Day S, Talbot DJ. Editorial: Statistical guidelines for clinical trials. Journal of the Royal Statistical Society, Series A 2000; 163:1-3.
17. EFSPI Working Group. Qualified statisticians in the European pharmaceutical industry: report of a European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) Working Group. Drug Information Journal 1999; 33:407-415.
18. ICH E9 Expert Working Group. Statistical Principles for Clinical Trials: ICH Harmonised Tripartite Guideline. Statistics in Medicine 1999; 18:1905-1942.
19. Lewis JA. Statistical Principles for Clinical Trials: an introductory note on an international guideline. Statistics in Medicine 1999; 18:1903-1904.
20. Lewis JA, Jones DR, Roehmel J. Biostatistical methodology in clinical trials - a European guideline. Statistics in Medicine 1995; 14:1655-1682.
21. Lewis J, Louv W, Rockhold F, Sato T. The impact of the guideline entitled Statistical Principles for Clinical Trials (ICH E9). Statistics in Medicine 2001; 22:2549-2560.
22. MHW. Guideline for the statistical analysis of clinical trials. Ministry of Health and Welfare, Pharmaceutical Affairs Bureau, Tokyo, Japan, 1992.
23. Phillips A, Ebbutt A, France L, Morgan D. The International Conference on Harmonization Guideline 'Statistical Principles for Clinical Trials': issues in applying the guideline in practice. Drug Information Journal 2000; 34:337-348.
24. JPMA emphasizes importance of biological statisticians. Comline - Emerging Markets of Japan and Eastern Asia: Health Care & Biotechnology 1998: 1:17.
25. ICH unlikely to lead to Pharma innovation. Marketletter 1998, pNA.
26. ICH aims to boost industry support for drug harmonization. Europe Drug & Device Report 2000; 10/4.
27. D'Arcy PF, Harron DWG. Proceedings of The Fourth International Conference on Harmonisation, Brussels 1997.
28. Cone M. Proceedings of The Fifth International Conference on Harmonisation, San Diego 2000.